本帖最后由 老马 于 2013-3-13 13:43 编辑 ! W, t7 n1 w; ]' `- a
" z s4 g! R4 t7 L p健择(吉西他滨)+顺铂+阿瓦斯汀7 p" q5 L- ^" d+ K! [
Gemzar +Cisplatin + Avastin. F! q& g0 x' p% t, e& W* q
http://annonc.oxfordjournals.org/content/21/9/1804.full y% z2 Y x/ ~( F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 e) q5 R0 V/ zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ) `6 x: U( H% \; {9 C( s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) i; z2 P1 q3 a+ @( e' F: [9 U
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 839)
3 N4 l x- V3 u4 n- W" d( i华为网盘附件:
: c& W" w' f1 C1 P5 S- L+ N【华为网盘】ava.JPG. e. b8 v! U+ k x, u
|